183 related articles for article (PubMed ID: 23016949)
1. Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study.
Hawwa AF; Westwood PM; Collier PS; Millership JS; Yakkundi S; Thurley G; Shields MD; Nunn AJ; Halliday HL; McElnay JC
Br J Clin Pharmacol; 2013 May; 75(5):1265-76. PubMed ID: 23016949
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of ranitidine in critically ill infants.
Wiest DB; O'Neal W; Reigart JR; Brundage RC; Gillette PC; Yost RL
Dev Pharmacol Ther; 1989; 12(1):7-12. PubMed ID: 2785905
[TBL] [Abstract][Full Text] [Related]
3. Gastric pH control in critically ill children receiving intravenous ranitidine.
Harrison AM; Lugo RA; Vernon DD
Crit Care Med; 1998 Aug; 26(8):1433-6. PubMed ID: 9710105
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children.
Lugo RA; Harrison AM; Cash J; Sweeley J; Vernon DD
Crit Care Med; 2001 Apr; 29(4):759-64. PubMed ID: 11373465
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
James LP; Stowe CD; Farrar HC; Menendez AA; Argao EA
J Clin Pharmacol; 1999 Dec; 39(12):1242-7. PubMed ID: 10586389
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H; Böttcher MF; Ochmann K
Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
[TBL] [Abstract][Full Text] [Related]
8. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux.
Orenstein SR; Blumer JL; Faessel HM; McGuire JA; Fung K; Li BU; Lavine JE; Grunow JE; Treem WR; Ciociola AA
Aliment Pharmacol Ther; 2002 May; 16(5):899-907. PubMed ID: 11966498
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Madani S; Kauffman R; Simpson P; Lehr VT; Lai ML; Sarniak A; Tolia V
J Clin Pharmacol; 2014 Feb; 54(2):201-5. PubMed ID: 24258773
[TBL] [Abstract][Full Text] [Related]
10. Developmental pharmacokinetics and pharmacodynamics of nizatidine.
Abdel-Rahman SM; Johnson FK; Connor JD; Staiano A; Dupont C; Tolia V; Winter H; Gauthier-Dubois G; Kearns GL
J Pediatr Gastroenterol Nutr; 2004 Apr; 38(4):442-51. PubMed ID: 15085026
[TBL] [Abstract][Full Text] [Related]
11. Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children.
Osteyee JL; Banner W
Am J Crit Care; 1994 Jul; 3(4):267-72. PubMed ID: 7920954
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
McLeay SC; Green B; Treem W; Thyssen A; Mannaert E; Kimko H
Clin Pharmacokinet; 2014 Oct; 53(10):943-57. PubMed ID: 25168707
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling of oral ranitidine: implications in efficacy and safety.
Franco C; Flores-Murrieta FJ; Castañeda-Hernández G
Proc West Pharmacol Soc; 1997; 40():107-9. PubMed ID: 9436228
[No Abstract] [Full Text] [Related]
16. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers.
Flores Pérez J; Juárez Olguín H; Flores Pérez C; Pérez Guillé G; Guillé Pérez A; Camacho Vieyra A; Toledo López A; Carrasco Portugal M; Lares Asseff I
Chronobiol Int; 2003 May; 20(3):485-94. PubMed ID: 12868543
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux.
Asseff IL; Gaucin GB; Olguín HJ; Nájera JA; López AT; Guillé GP; Torres FZ
BMC Pediatr; 2016 Jul; 16():90. PubMed ID: 27412521
[TBL] [Abstract][Full Text] [Related]
18. Do H2 receptor antagonists have a therapeutic role in childhood?
Kelly DA
J Pediatr Gastroenterol Nutr; 1994 Oct; 19(3):270-6. PubMed ID: 7815256
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.
Zhou Q; Ruan ZR; Yuan H; Jiang B; Xu DH
World J Gastroenterol; 2006 May; 12(17):2742-8. PubMed ID: 16718762
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and pharmacokinetics of parenteral histamine (H2)-receptor antagonists.
Ostro MJ
Am J Med; 1987 Dec; 83(6A):15-22. PubMed ID: 2892405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
